Treace's Paradox: Surgeon Growth Meets Pricing Pressure

PONTE VEDRA, Fla. – February 27, 2026 – Treace Medical Concepts, Inc. (NasdaqGS: TMCI) presented a complex financial narrative in its latest earnings report, revealing a company successfully managing costs and expanding its user base while navigating significant pricing pressures that have clouded its short-term revenue forecast.

For the full year of 2025, the medical technology firm, known for its innovative Lapiplasty® 3D Bunion Correction® System, posted a 2% revenue increase to $212.7 million. However, the fourth quarter told a different story, with revenue falling 9% to $62.5 million compared to the same period in 2024. This decline occurred even as the company grew its active surgeon base by 6% and made substantial strides in financial discipline, cutting its full-year cash usage by 46%.

The results highlight a critical inflection point for Treace: the strategic, yet initially painful, embrace of a broader product portfolio that includes lower-priced options. While the company projects a potential revenue decline of up to 6% for 2026, it is betting that this expanded strategy will secure greater market share and fuel a return to growth in the long run.

The Strategic Shift to Lower-Priced Kits

The primary driver behind the fourth-quarter revenue dip was not a drop in procedural volume but a deliberate, demand-driven pivot. The company’s earnings release directly attributed the decrease to a "shift in product sales toward lower priced bunion kits." This reflects a broader trend in the orthopedic market and a strategic expansion by Treace beyond its flagship, higher-priced Lapiplasty® system.

In recent years, Treace has launched several new systems aimed at minimally invasive surgery (MIS), including the Nanoplasty® and Percuplasty™ systems. These products are designed to appeal to a wider range of surgeons who prefer less invasive techniques, which can offer patients smaller incisions and faster recovery times. While these MIS kits expand Treace's addressable market, they come at a lower price point per procedure, directly impacting topline revenue figures when they cannibalize or outpace sales of the premium Lapiplasty® system.

The company noted that case volume growth was in the mid-single digits during the fourth quarter, indicating that more surgeons are performing procedures with Treace products. The challenge lies in the revenue generated per case. This product mix shift is a calculated trade-off: sacrificing some revenue per procedure today to capture a larger portion of the estimated 1.1 million annual surgical candidates for bunions in the U.S.

Competing in an Evolving Surgical Landscape

Treace's strategic pivot is unfolding within a highly competitive and rapidly evolving bunion surgery market. The global market, valued at nearly $450 million in 2024, is projected to grow at over 5% annually, largely fueled by the increasing adoption of MIS techniques. Patients and surgeons alike are drawn to the benefits of less invasive approaches, a trend that is reshaping product development and corporate strategy across the industry.

Major orthopedic players are vying for dominance in this space. Stryker offers its PROstep™ MIS system, a legacy of its acquisition of Wright Medical, which emphasizes a quicker return to function for patients. Similarly, Arthrex promotes its own Minimally Invasive Bunionectomy System, highlighting decreased pain and swelling. The entry of giants like Johnson & Johnson's DePuy Synthes with new plating systems further intensifies the competitive pressure.

Within this context, Treace's expansion into MIS is not just an option but a necessity to maintain its leadership position. By offering a comprehensive suite of five instrumented systems, the company aims to cater to nearly all surgeon preferences across different types of bunion deformities. This diversification transforms Treace from a single-product innovator into a broad-based bunion solutions provider, positioning it to compete on all fronts.

A Foundation for Future Growth

Despite the immediate revenue headwinds and a cautious 2026 forecast, Treace's leadership is framing the current period as a strategic transition. The company is laying the groundwork for a return to growth, which it anticipates will materialize in the second half of the year.

"In 2026, we expect our expanded bunion portfolio and forthcoming product launches to deliver continued market share gains and restore topline growth in the back half of the year,” said John T. Treace, the company's CEO and Chairman, in a statement.

This confidence is built on several key pillars. The first is the growing surgeon base, which ended 2025 at 3,337 active users—a 6% annual increase. This base represents a significant foothold, comprising roughly one-third of the estimated 10,000 U.S. surgeons who perform bunion surgery. Treace's expanded portfolio is designed to increase its "wallet share" with these existing customers while attracting new ones who were previously unserved by the Lapiplasty-only offering. Another pillar is continued innovation, with the planned 2026 commercialization of Lapiplasty Lightning™, a next-generation platform designed to make the core procedure simpler and faster.

Fortifying Financial Health for the Long Haul

While the market focuses on the topline revenue figures, the underlying story of Treace's 2025 performance is one of significant financial fortification. The company demonstrated impressive operational discipline, slashing its full-year cash usage by 46% to $27.3 million and narrowing its adjusted EBITDA loss by 64% to just $(3.9) million.

This improved efficiency provides a crucial runway to execute its long-term strategy. Further bolstering its position, Treace secured a new five-year, $175 million senior secured loan arrangement in December 2025. This deal provides immediate access to capital and up to $165 million in total liquidity, ensuring the company is well-funded to support its product launches and R&D pipeline without being constrained by short-term market fluctuations.

For the upcoming year, Treace has guided for revenue between $200 million and $212 million, representing a potential change of -6% to 0% from 2025. It also projects a slight increase in adjusted EBITDA loss to a range of $4.0 million to $6.0 million. This transparent guidance acknowledges the ongoing impact of the product mix shift, which the company expects to navigate as it pushes toward a planned resurgence later in the year.